目的: 从分组科学性与成本覆盖度验证国家DIP 2.0版在放疗病种中的应用价值,为医保支付方式改革提供实证依据。方法: 分析国家DIP 2.0版在放疗病种中的优化情况,再基于广州DIP 2025年版分析某医院放疗病种数据（1987例有效病例）,采用变异系数（CV）和总体变异减低系数（RIV）评价分组科学性,采用费用偏差、成本补偿率分析成本覆盖度。结果: 各分组CV值均小于0.7（未分组前为0.83）,组内同质性合理;RIV值为0.62,组间异质性良好。整体成本补偿率1.056,多数技术适配良好。结论: 国家DIP 2.0版显著优化了放疗技术识别精度与临床贴合度,分组效能与成本覆盖度较好,但仍存在提升空间,可进一步优化分组标准、新增适配首诊放疗的病种组。

Objective: The paper verifies the application value of the national DIP 2.0 version in radiotherapy diseases from the grouping scientificity and cost coverage, to provide empirical evidence for the reform of medical insurance payment. Methods: The paper analyzed the optimization of the national DIP 2.0 version in radiotherapy diseases. Based on data of radiotherapy diseases (1987 valid cases) from a hospital participating in the Guangzhou DIP 2025 version, the coefficient of variation (CV) and the reduction in variance (RIV) were used to evaluate the grouping scientificity, and cost deviation and cost compensation rate analysis were used to analyze cost coverage. Results: The CV of each group was less than 0.7 (0.83 before grouping), and the homogeneity within the groups was reasonable. The RIV value was 0.62, indicating good heterogeneity between groups. The overall cost compensation rate was 1.056, and most technologies were well adapted. Conclusions: The national DIP 2.0 version has significantly optimized the identification accuracy and clinical fit of radiotherapy techniques. The grouping efficacy and cost coverage are relatively good. The grouping standards can be further optimized and new disease groups suitable for first-visit radiotherapy can be added.